Poor survival with wild-type TP53 ovarian cancer?

OBJECTIVE The objective of this study is to investigate whether wild-type TP53 status in high-grade serous ovarian carcinoma is associated with poorer survival. METHODS Clinical and genomic data of 316 sequenced samples from The Cancer Genome Atlas (TCGA) ovarian high-grade serous carcinoma study were downloaded from TCGA data portal. Association between wild-type TP53 and survival was analyzed with Kaplan Meier method and Cox regression. The diagnosis of high-grade serous carcinomas was evaluated by reviewing pathological reports and high-resolution hematoxylin and eosin (H&E) images from frozen sections. The authenticity of wild-type TP53 in these tumor samples was assessed by analyzing SNP array data with ASCAT algorithm, reverse phase protein array (RPPA) data and RNAseq data. RESULTS Fifteen patients with high grade serous ovarian carcinomas were identified to have wild-type TP53, which had significantly shorter survival and higher chemoresistance than those with mutated TP53. The authenticity of wild-type TP53 status in these fifteen patients was supported by SNP array, RPPA, and RNAseq data. Except four cases with mixed histology, the classification as high grade serous carcinomas was supported by pathological reports and H&E images. Using RNAseq data, it was found that EDA2R gene, a direct target of wild-type TP53, was highly up-regulated in samples with wild-type TP53 in comparison to samples with either nonsense or missense TP53 mutations. CONCLUSION Although patients with wild-type TP53 ovarian cancer were rare in the TCGA high grade ovarian serous carcinomas cohort, these patients appeared to have a poorer survival and were more chemoresistant than those with mutated TP53. Differentially expressed genes in these TP53 wild-type tumors may provide insight in the molecular mechanism in chemotherapy resistance.

[1]  Yusuke Nakamura,et al.  Crosstalk of EDA-A2/XEDAR in the p53 Signaling Pathway , 2010, Molecular Cancer Research.

[2]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[3]  Gong Yang,et al.  The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer , 2011, Clinical Cancer Research.

[4]  A. Sood,et al.  Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.

[5]  A. Spurdle,et al.  High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. , 2013, Gynecologic oncology.

[6]  A. Fornace,et al.  Genomic instability and the role of p53 mutations in cancer cells. , 1995, Current opinion in oncology.

[7]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[8]  A. Crijns,et al.  Modest effect of p 53 , EGFR and HER-2 / neu on prognosis in epithelial ovarian cancer : a meta-analysis , 2009 .

[9]  K. Wong,et al.  Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. , 2012, Endocrinology.

[10]  K. Mimori,et al.  p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. , 2009, Cancer research.

[11]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[12]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[13]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Hauptmann,et al.  Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival , 2008, Clinical Cancer Research.

[15]  Kevin R. Coombes,et al.  Variable slope normalization of reverse phase protein arrays , 2009, Bioinform..

[16]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[17]  I. Jacobs,et al.  Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  S. Kapoor.  The emerging anti-proliferative role of Nutlin-3 in the pathogenesis of systemic malignancies , 2013, Cancer biology & therapy.

[19]  T. Bonome,et al.  Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[20]  M. Hentze,et al.  A Perfect Message RNA Surveillance and Nonsense-Mediated Decay , 1999, Cell.

[21]  P. Chaudhary,et al.  Role of TRAF3 and -6 in the Activation of the NF-κB and JNK Pathways by X-linked Ectodermal Dysplasia Receptor* , 2002, The Journal of Biological Chemistry.

[22]  A. Børresen-Dale,et al.  Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.

[23]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Allan Balmain,et al.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene , 2004, Nature.

[25]  A. El‐Naggar,et al.  p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. , 2012, Cancer cell.

[26]  Hong Wu,et al.  Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. , 2009, Gynecologic oncology.

[27]  I. Shih,et al.  Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance , 2007, International Journal of Gynecologic Cancer.

[28]  J. Pietenpol,et al.  Targeting mutant p53 in human tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Donald R Schwartz,et al.  Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. , 2003, Cancer cell.